Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist

British Journal of Pharmacology

Volumn 123, Issue 7, 1998, Pages 1317-1324

  Wright, D Hamish ^a   Metters, Kathleen M ^b   Abramovitz, Mark ^b   Ford Hutchinson, Anthony W ^b  

^a MCGILL UNIVERSITY   (Canada)

^b MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

DP; Prostaglandin D2; Prostaglandin J2; Prostanoid receptor; Recombinant; Selective agonist

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; 4 (3 (3 (3 HYDROXYOCTYL) 4 OXO 2 THIAZOLIDINYL)PROPYL)BENZOIC ACID; 4 [3 [3 (3 HYDROXYOCTYL) 4 OXO 2 THIAZOLIDINYL]PROPYL]BENZOIC ACID; 5 (6 CARBOXYHEXYL) 1 (3 CYCLOHEXYL 3 HYDROXYPROPYL)HYDANTOIN; 9BETA CHLORO 15 CYCLOHEXYL 9 DEOXY 16,17,18,19,20 PENTANORPROSTAGLANDIN F2 ALPHA; BENZOIC ACID DERIVATIVE; CYCLIC AMP; DELTA12 PROSTAGLANDIN J2; PROSTAGLANDIN D2; PROSTAGLANDIN J2; PROSTANOID RECEPTOR; RECOMBINANT RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; KIDNEY CELL; LIGAND BINDING; PRIORITY JOURNAL; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION;

ADENINE NUCLEOTIDES; BENZOATES; BINDING, COMPETITIVE; CELL LINE; CYCLIC AMP; DINOPROSTONE; GUANINE NUCLEOTIDES; HUMANS; KINETICS; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECOMBINANT PROTEINS; THIAZOLES; THIAZOLIDINES; TRITIUM;

EID: 0031913845     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701708     Document Type: Article

References (45)

1. ABRAMOVITZ, M., BOIE, Y., NGUYEN, T., RUSHMORE, T.H., BAYNE, M.A., METTERS, K.M., SLIPETZ, D.M. & GRYGORZCYK, R. (1994). Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem., 269, 2632-2636.
2. 3 prostanoid receptor. FEBS Lett., 338, 170-174.
3. 2. Biochem. Biophys. Res. Commun., 197, 263-270.
4. ARMSTRONG, R.A., LAWRENCE, R.A., JONES, R.L., WILSON, N.H. & COLLIER, A. (1989). Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors. Br. J. Pharmacol., 97, 657-668.
5. BARRACLOUGH, P., BOLOFO, M.L., GILES, H., GILLAM, J., HARRIS, C.J., KELLY, M.G., LEFF, P., MCNEILL, A., ROBERTSON, A.D., STEPNEY, R.J. & WHITTLE, B.J.R. (1996). Synthesis of hexahydrocyclopentimidazol-2-(1H)-one derivatives displaying selective DP-receptor agonist properties. Bioorg. Med. Chem., 4, 81-90.
6. 2 subtype. J. Biol. Chem., 269, 11873-11877.
7. BOIE, Y., RUSHMORE, T.H., DARMON-GOODWIN, A., GRYGORCZYK, R., SLIPETZ, D.M., METTERS, K.M. & ABRAMOVITZ, M. (1994). Cloning and expression of a cDNA for the human prostanoid IP receptor. J. Biol. Chem., 269, 12173-12178.
8. BOIE, Y., SAWYER, N., SLIPETZ, D.M., METTERS, K.M. & ABRAMOVITZ, M. (1995). Molecular cloning and characterization of the human prostanoid DP receptor. J. Biol. Chem., 270, 18910-18916.
9. BROCKWELL, M.A., CALDWELL, A.C., WHITTAKER, N. & BEGLEY, M.J. (1981). Heterocyclic prostaglandin analogues. Part 3. The relationship of configuration to biological activity for some hydantoin prostaglandin analogues. J. Chem. Soc. Perkin Trans., 1, 706-711.
10. 3 receptors. In Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 21, ed. Samuelsson, B., Ramwell P.W., Paoletti, R., Falco, G. & Granstrom, E. pp. 379-382. New York: Raven Press.
11. COLEMAN, R.A., HUMPHREY, P.P.A., KENNEDY, I. & LUMLEY, P. (1984). Prostanoid receptors - the development of a working classification. Trends Pharmacol. Sci., 5, 303-306.
12. COLEMAN, R.A., SMITH, W.L. & NARUMIYA, S. (1994). VIII. International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev., 46, 205-229.
13. DONG, Y.J., JONES, R.L. & WILSON, N.H. (1986). Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogies. Br. J. Pharmacol., 87, 97-107.
14. FELDMAN, H.A. (1972). Mathematical theory of complex ligand binding systems at equilibrium: methods of parameter fitting. Anal. Biochem., 48, 317-338.
15. FELGNER, P.L., GADEK, T.R., HOLM, M., ROMAN, R., CHAN, H.W., WENZ, M., NORTHROP, J.P., RINGOLD, G.M. & DANIELSEN, M. (1987). Lipofection: a high efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U.S.A., 84, 7413-7417.
16. FERNANDES, B. & CRANKSHAW, D. (1995). Functional characterization of the prostanoid DP receptor in human myometrium. Eur. J. Pharmacol., 283, 73-81.
17. 2, identification of products formed in vitro. J. Biol. Chem., 258, 11713-11718.
18. FUNK, C.D., FURCI, L., FITZGERALD, G.A., GRYGORCZYK, R., ROCHETTE, C., BAYNE, M.A., ABRAMOVITZ, M., ADAM, M. & METTERS, K.M. (1993). Cloning and expression of a cDNA for the human prostaglandin E receptor EP1 subtype. J. Biol. Chem., 268, 26767-26772.
19. GILES, H., LEFF, P., BOLOFO, M.L., KELLY, M.G. & ROBERTSON, A.D. (1989). The classification of prostaglandin DP-receptors in platelets and vasculature using BW A868C, a novel, selective and potent competitive antagonist. Br. J. Pharmacol., 96, 291-300.
20. GILMAN, A.G. (1987). G proteins: transducers of receptor-generated signals. Ann. Rev. Biochem., 56, 615-649.
21. HANSKI, E., STERNWEIS, P.C., NORTHUP, J.K., DROMERICK, A.W. & GILMAN, A.G. (1981). The regulatory component of adenylate cyclase. Purification and properties of the turkey erythrocyte protein. J. Biol. Chem., 256, 12911-12919.
22. 2 receptor. Nature, 349, 617-620.
23. HIRATA, M., KAKIZUKA, A., AIZAWA, M., USHIKUBI, F. & NARUMIYA, S. (1994). Molecular characterization of a mouse prostaglandin D receptor and functional expression of the cloned gene. Proc. Natl. Acad. Sci. U.S.A., 91, 11192-11196.
24. 2: a biochemical perspective. Prostaglandins Leukotrienes Essent. Fatty Acids, 37, 219-234.
25. KENNEDY, I., COLEMAN, R.A., HUMPHREY, P.P.A., LEVY, G.P. & LUMLEY, P. (1982). Studies on the characterization of prostanoid receptors: a proposed classification. Prostaglandins, 24, 667-689.
26. KOTANI, M., TANAKA, I., OGAWA, Y., UNSUI, T., MORI, K., ICHIKAWA, A., NARUMIYA, S., YOSHIMI, T. & NAKAO, K. (1995). Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol., 48, 869-879.
27. 2. Prostaglandins Leukotrienes Med., 16, 131-146.
28. 2 receptor stimulation elicits ocular hypotensive effects in rabbits and cats. Eur. J. Pharmacol., 275, 245-250.
29. 2 and its analogues. Br. J. Pharmacol., 85, 367-375.
30. NEER, E.J. (1995). Heterotrimeric G-proteins: organizers of transmembrane signals. Cell, 80, 249-257.
31. 2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils. Eicosanoids, 4, 21-28.
32. RANGACHARI, P.K., BETTI, P.A., PRIOR, E.T. & ROBERTS II, L.J. (1995). Effects of a selective DP receptor agonist (BW245C) and antagonist (BW A868C) on the canine colonic epithelium: an argument for a different DP receptor. J. Pharmacol. Exp. Ther., 275, 611-617.
33. RAYCHOWDHURY, M.K., YUKAWA, M., COLLINS, L.J., MCGRAIL, S.H., KENT, K.C. & WARE, J.C. (1995). Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J. Biol. Chem., 270, 7011-7014.
34. 2 subtype. Mol. Pharmacol., 46, 213-220.
35. ROJAS, F.J. & BIRMBAUMER, L. (1985). Regulation of glucagon receptor binding. Lack of effect of Mg and preferential role for GDP. J. Biol. Chem., 260, 7829-7835.
36. 2. Eur. J. Biochem., 228, 23-30.
37. SCHULZ, B.G., BECKMAN, R., MÜLLER, B., SCHRÖDER, G., MAASS, B., THIERAUCH, K.-H., BUCHMANN, B., VERHALLEN, P.F.J. & FRÖHLICH, W. (1990). Cardio-and hemodynamic profile of selective PGD2 analogues. In Advances in Prostaglandin, Thromboxane and Leukotriene Research, Vol. 21, ed. Samuelsson, B., Ramwell, P.W., Paoletti, R., Falco, G. & Granstrom, E. 591-594. New York: Raven Press.
38. SENIOR, J., SANGHA, R., BAXTER, G.S., MARSHALL, K., & CLAYTON, J.K. (1992). In vitro characterization of prostanoid FP-, DP-, IP-and TP-receptors on the non-pregnant human myometrium. Br. J. Pharmacol., 107, 215-221.
39. 1 and IP receptor agonist. Br. J. Pharmacol., 94, 334P.
40. STERNWEIS, P.C., NORTHUP, J.K., SMIGEL, M.D. & OILMAN, A.G. (1981). The regulatory component of adenylate cyclase. Purification and properties. J. Biol. Chem., 256, 11517-11526.
41. 2 receptor. Prostaglandins, 35, 855-868.
42. 2 receptor. Prostaglandins, 25, 13-28.
43. 2 and BW245C activation of human platelet adenylate cyclase. Br. J. Pharmacol., 96, 301-306.
44. WHITTLE, B.J.R., MONCADA, S., MULLANE, K. & VANE, J.R. (1983). Platelet and cardiovascular activity of the hydantoin BW245C, a potent prostaglandin analogue. Prostaglandins, 25, 205-223.
45. 2. Inv. Opthamol. Vis. Sci., 31, 138-146.